Pulse Biosciences (NASDAQ:PLSE) Shares Down 7.8% – Here’s Why

Pulse Biosciences, Inc. (NASDAQ:PLSE) fell 7.8% on Wednesday . The stock traded as low as $20.46 and last traded at $20.18. 125,583 shares traded hands during trading, a decline of 16% from the average session volume of 149,235 shares. The stock had previously closed at $21.89.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded Pulse Biosciences to a “sell” rating in a research report on Thursday, January 2nd.

Pulse Biosciences Trading Down 7.4 %

The company has a 50-day moving average of $19.07 and a two-hundred day moving average of $18.20.

Insider Activity at Pulse Biosciences

In other Pulse Biosciences news, Director Robert W. Duggan acquired 55,256 shares of the stock in a transaction dated Friday, December 13th. The shares were acquired at an average cost of $17.18 per share, for a total transaction of $949,298.08. Following the completion of the transaction, the director now directly owns 42,328,717 shares of the company’s stock, valued at approximately $727,207,358.06. The trade was a 0.13 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Burke Thomas Barrett sold 50,000 shares of the business’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $17.42, for a total value of $871,000.00. Following the completion of the transaction, the chief executive officer now owns 63,172 shares in the company, valued at $1,100,456.24. The trade was a 44.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 71.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Pulse Biosciences

Large investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC lifted its position in shares of Pulse Biosciences by 98.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,692 shares of the company’s stock worth $29,000 after buying an additional 838 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of Pulse Biosciences in the fourth quarter worth about $44,000. Caisse Des Depots ET Consignations purchased a new stake in shares of Pulse Biosciences in the fourth quarter worth about $95,000. Farther Finance Advisors LLC lifted its position in shares of Pulse Biosciences by 44.4% in the fourth quarter. Farther Finance Advisors LLC now owns 7,220 shares of the company’s stock worth $126,000 after buying an additional 2,220 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new stake in shares of Pulse Biosciences in the fourth quarter worth about $193,000. 76.95% of the stock is currently owned by hedge funds and other institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.